Across TCGA pan-cancer cohorts, MRPS6 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated MRPS6 data layer compared with 26 for mass-spec protein and 3 for mass-spec protein.
The strongest signal is observed in colon adenocarcinoma (COAD), where higher MRPS6 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MRPS6 expression acts as an unfavorable survival marker.
COAD are the cancer types where MRPS6 Mutation most reproducibly stratifies survival.